OCALA, Fla., Sept. 21, 2022 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. AMERICAN (“AIM” or the “Company”), an immunopharmaceutical company focused on the discovery and development of therapeutics to treat multiple types of cancer, immune disorders and viral diseases, including COVID-19, the disease caused by SARS. CoV-2 virus, announced today that it will participate in the Virtual Investor Long COVID Event on Wednesday, September 28, 2022 at 3:00 p.m. ET.
As part of the virtual event, Thomas K. Equels, MS JD, Chief Executive Officer of AIM ImmunoTech, will be joined by Key Opinion Leaders Dr. Charles Lapp of the Hunter-Hopkins Center in Charlotte, NC, and Dr. Daniel Peterson of Sierra Internal is joining Medicine in Incline Village, Nevada to discuss the company’s ongoing FDA-approved Expanded Access Program for its investigational drug Ampligen, which focuses on the use and evaluation of the drug in patients with symptoms of a “long COVID” extends.
In addition to the moderated part of the event, investors and interested parties have the opportunity to submit questions live during the event. The company will answer as many questions as possible during the event.
A live video webcast of the Virtual Investor Long COVID event will be available on Events & Presentations Investor Relations page of the company’s website (aimimmuno.com). A webcast replay will be available two hours after the live presentation and will be archived for 90 days.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immunopharmaceutical company focused on the discovery and development of therapeutics to treat multiple types of cancer, immune disorders and viral diseases, including COVID-19. The company’s flagship product, Ampligen® (Rintatolimod) is a broad-spectrum immunomodulator in development for global cancers, viral diseases and immune system disorders.
For more information, please visit aimimmuno.com and connect with the company Twitter,
